The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 17, 2018
Filed:
Jan. 08, 2013
Dieter Huesken, Basel, CH;
Brian Bettencourt, Cambridge, MA (US);
David Bumcrot, Cambridge, MA (US);
Satyanarayana Kuchimanchi, Cambridge, MA (US);
Stuart Milstein, Cambridge, MA (US);
Michael Schlabach, Jr., Cambridge, MA (US);
Frank P. Stegmeier, Cambridge, MA (US);
Markus Warmuth, Cambridge, MA (US);
Jan Weiler, Cambridge, MA (US);
Novartis Ag, Basel, CH;
Brian Richard Bettencourt, Cambridge, MA (US);
David Anton Bumcrot, Cambridge, MA (US);
Dieter Huesken, Freiburg i. Br., DE;
Satyanarayana Kuchimanchi, Cambridge, MA (US);
Stuart Milstein, Cambridge, MA (US);
Michael Ray Schlabach, Jr., Cambridge, MA (US);
Frank Peter Stegmeier, Acton, MA (US);
Markus Warmuth, Natick, MA (US);
Jan Weiler, Cambridge, MA (US);
Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);
Abstract
The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.